AbbVie

News

Apogee buy delivers eczema trial win for AbbVie

AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.

News

AbbVie's Cerevel takeover delivers Parkinson's approval

The first drug from AbbVie's $8.7 billion takeover of Cerevel two years ago, Parkinson's disease therapy Juvmo, has won FDA approval.

News

Iambic files IPO after signing up AbbVie as new partner

In the space of a day, Iambic has filed an IPO, released the latest version of its AI platform, and signed a multi-year alliance with AbbVie.

News

Bottle of Qulipta superimposed on image of woman holding head against sun dappled wall

AbbVie charts a new course for CGRPs in menstrual migraine

AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual migraine.

News

AbbVie's cancer TCE etentamig hits the mark in myeloma

AbbVie has reported positive results with CD3xBCMA bispecific etentamig in multiple myeloma, but can it break into a crowded market?

News

Another 340B lawsuit gets underway, in Illinois

Three pharma groups have opened a new front in their legal challenge to the federal 340B drug pricing programme in the US.

Apogee buy delivers eczema trial win for AbbVie

AbbVie's Cerevel takeover delivers Parkinson's approval

Iambic files IPO after signing up AbbVie as new partner

AbbVie charts a new course for CGRPs in menstrual migraine

AbbVie's cancer TCE etentamig hits the mark in myeloma

Another 340B lawsuit gets underway, in Illinois

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks